Andy Chien, MD, PhD
Our group studies several cancer models, with a focus on malignant melanoma. Specifically, we are interested in how complex signaling pathways regulate melanoma cell fate and tumor progression, particularly with regards to populations considered to be tumor stem cells. Our goal is to develop therapeutic approaches that can alter tumor-initiating potential in melanoma cells in order to prolong survival for patients with metastatic disease. In parallel, we are performing similar studies in other refractory cancer models.